The treatment with verapamil enhanced Trx-R activity and significantly inhibited TLR4, TXNIP, and NLRP3 inflammatory bodies, thereby preventing the progression of diabetic retinopathy. The gene discussed is TXNIP; the disease is diabetic retinopathy.